Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Bone and Mineral Metabolism"
DOI: 10.1007/s00774-018-0904-5
Abstract: This study examined differences between men and women in factors affecting anti-osteoporosis drug treatment after osteoporotic fracture. Using a national claims database, we analyzed patients aged 50Â years and older who experienced their first osteoporotic fracture… read more here.
Keywords: osteoporosis drug; treatment; anti osteoporosis; fracture ... See more keywords
Identification of Fibroblast Activation Protein as an Osteogenic Suppressor and Anti-osteoporosis Drug Target.
Sign Up to like & getrecommendations! Published in 2020 at "Cell reports"
DOI: 10.1016/j.celrep.2020.108252
Abstract: Osteogenic suppressors such as Sclerostin not only regulate skeletal development and regeneration but also serve as anti-osteoporosis drug targets. However, very few druggable suppressors have been identified due to limited understanding of the molecular mechanisms… read more here.
Keywords: anti osteoporosis; drug; fibroblast activation; osteoporosis drug ... See more keywords
Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply.
Sign Up to like & getrecommendations! Published in 2018 at "Rheumatology"
DOI: 10.1093/rheumatology/kex430
Abstract: _SIR,_ We are grateful to Dr Armstrong for sharing his views and concerns about our recent paper that elicited patients’ preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE). First, the correspondent questioned… read more here.
Keywords: cross european; drug treatment; european discrete; discrete choice ... See more keywords